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Abstract
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare disease that is classically described as presen-
ting with cough, dyspnea, and wheezing in non-smoker middle aged females. Pulmonary function tests commonly demonstrate 
an obstructive pattern and CT of chest usually reveals diffuse air trapping with mosaic pattern. We present a case of patient with 
DIPNECH manifesting with restrictive pattern and as usual interstitial pneumonia on imaging. 
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Introduction
Diffuse idiopathic pulmonary neuroendocri-
ne cell hyperplasia (DIPNECH) is a rare disorder 
with much knowledge about its diagnosis and 
treatment based on reported cases. We present 
a case of a patient who presented with exertio-
nal dyspnea and evidence of usual interstitial 
pneumonia on imaging. We briefly describe the 
diagnosis and therapeutic options for DIPNECH 
described in literature. 
Case presentation
A 66-year-old female non-smoker presented 
to clinic with progressively worsening shortness 
of breath on exertion and non-productive cough of 
several months’ duration. She denied orthopnea, 
paroxysmal nocturnal dyspnea, or edema. Her co-
morbidities included hypertension and coronary 
artery disease. She did not report any significant 
environmental exposures or family history of lung 
diseases. She did not have any history of rheuma-
tic or collagen vascular disease. Physical exami-
nation was significant for bilateral wheezing and 
fine end inspiratory crackles at the lung bases. 
Pulmonary function tests (PFTs) demonstrated 
a  restrictive pattern with reduced FEV1 & FVC 
(42% and 40% of predicted respectively) but 
preserved FEV1/FVC ratio; decreased TLC (2.76 l 
[54% of predicted]); and reduced DLCO (47%). 
Chest X-ray demonstrated extensively increased 
interstitial markings with fibronodular character. 
High resolution computed tomography (HRCT) of 
chest showed diffuse sub-pleural reticulation and 
honeycombing involving both upper and lower 
lobes (Figs 1A, B). The results of the laboratory 
tests ANA, ESR, CRP, CBC, Serum IgE including 
bronchoalveolar lavage (BAL) components were 
in normal range. Microscopic examination of the 
lung biopsy (the wedge resection sample perfor-
med via video assisted thoracoscopic surgery 
[VATS]) showed interstitial fibrosis and focal 
bronchiolar neuroendocrine cell hyperplasia 
with multiple carcinoid tumorlets (< 5 mm). The 
positive immunoreaction with antibody against 
synaptophysin confirmed neuroendocrine nature 
of these cells (< 5 mm) (Figs 2A, B). Her serum 
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Figure 1A, B. High resolution Computed Tomography (HRCT) of chest demonstrating diffuse interstitial fibrosis and sub-pleural honeycombing 
involving both upper and lower lobes 
A B
Figure 2. A — tests of polygonal cells (black arrow) with oval nuclei and granular chromatin, measuring 2mm in maximum dimension, embedded 
in a background of interstitial fibrosis. The bronchiole is found to have an increased number of subepithelial cells (white arrow) with oval, granular 
nuclei consistent with neuroendocrine features. (H&E, primary magnification 4 ×). Inset High power view of nest of polygonal cells with granular, 
“salt and pepper” chromatin (H&E, primary magnification 40 ×). B — positive immunohistochemical staining for synaptophysin highlights the neu-
roendocrine nature of the nested cells and hyperplastic subepithelial cells, which are restricted to the basement membrane (black arrow) (primary 
magnification 4 ×)
chromogranin A (CgA) was elevated at 276 ng/ml 
(normal range: 0−95 ng/ml). Somatostatin recep-
tor scintigraphy (octreotide scan) revealed diffu-
se, intense radiotracer activity in bilateral lungs 
(Fig. 3). The listed above evidence allowed the 
diagnosis of DIPNECH with associated tumorlets. 
The patient was treated with corticosteroids and 
azithromycin, however, without apparent impro-
vement. Given the presence of carcinoid tumor-
lets and an avid diffuse uptake of radiotracer on 
octreotide scan, she was started on long acting 
octreotide therapy. After a few weeks of therapy, 
she experienced better control of her symptoms 
and improvement in her functional status. CT 
performed after one year showed stabilization of 
the pulmonary changes. 
Discussion
Pulmonary neuroendocrine cells (PNEC) are 
specialized epithelial cells located throughout 
the respiratory tract. These cells undergo reacti-
ve hyperplasia in chronic smokers or in response 
to hypoxia in patients with underlying lung dise-
ase or those living at high altitude [1]. The pre-
sence of diffuse proliferation of PNEC without 
the aforementioned risk factors is suggestive of 
DIPNECH. It is more prevalent in females (92%) 
with a mean age at presentation of 58 years [2]. 
Based on a  review of literature by Nassar et 
al., the most common presenting symptoms 
reported are cough (71%), dyspnea (63%), and 
wheezing (25%) [2]. The most common finding 
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Figure 3. Somatostatin receptor scintigraphy significant for diffuse, intense radiotracer activity in bilateral lungs
on PFTs were an irreversible obstructive defect 
(54−78% of patients), however, mixed (17%), and 
restrictive pattern (13%) were also noted [2]. The 
presence of different types of PFT patterns can 
be explained by the underlying pathophysiology. 
Constrictive bronchiolitis resulting in luminal 
narrowing and mural scarring can be associa-
ted with DIPNECH and give rise to obstructive 
symptoms. The secretion of peptides by the same 
hyperplastic PNEC can also lead to interstitial 
fibrosis and restrictive physiology as well [3, 4]. 
In the series of patients with DIPNECH re-
ported by Aguayo et al; all but one patient had 
diffuse reticulonodular opacities on chest X-ray 
(CXR) [1]. Single or multiple pulmonary nodules 
were the most common CT finding in patients 
with DIPNECH [2]. Mosaic perfusion is also a very 
commonly reported CT finding in DIPNECH that 
results from vasoconstriction in the areas of small 
airway obstruction [3]. Somatostatin receptor 
scintigraphy, also known as octreotide scan, is 
a very valuable investigation for detection and 
staging of neuroendocrine tumors [5]. It is based 
on the principle that neuroendocrine tumors have 
an over-expression of somatostatin receptors. The 
commonly used agent for octreotide scan is 111In
-pentetreotide which shows intense uptake by the 
tumor cells and the hyperplastic neuroendocrine 
cells in DIPNECH [6]. The role of octreotide scan in 
DIPNECH extends beyond detection and can help 
guide treatment strategies. It is postulated that the 
intensity of uptake of the radiotracer, which repre-
sents the density of somatostatin receptors, might 
predict the chances of therapeutic success with 
somatostatin analogues [7]. Our patient, who had 
an intense uptake of radiotracer in bilateral lungs 
responded very well to therapy with octreotide 
with resultant improvement in her functional 
status and decreased oxygen demand. 
The microscopic description of DIPNECH 
includes the presence of widespread hyperplasia 
of the pulmonary neuroendocrine cells confined 
to the bronchiolar epithelium. It is recognized as 
a preneoplastic lesion and patients with DIPNECH 
might have associated tumorlets (< 5 mm) or car-
cinoid tumors (> 5 mm). The latter two exhibit 
local invasion and carcinoid can be metastatic as 
well. The prevalence of DIPNECH in patients with 
resected carcinoid tumors of lung was reported 
to be 5.4% [8]. A large representative lung biopsy 
sample is required to confirm the diagnosis of 
DIPNECH with the use of ancillary immunohi-
stochemical staining for neuroendocrine mar-
kers like chromogranin, neuron specific enolase, 
and synaptophysin. Gorshtein et al. performed 
a retrospective analysis of 11 patients with DIP-
NECH including their biochemical analysis and 
found that serum CgA was elevated in 6 out of 
11 patients, however, 24-hour urine excretion of 
5-hydroxyindoleaceticacid (5-HIAA) was normal 
in all patients [6]. 
DIPNECH is classified as a preinvasive pre-
cursor to pulmonary carcinoid and tumorlets. 
However, most patients with DIPNECH have 
a stable clinical course [9]. Treatment with short 
acting beta agonists, inhaled corticosteroids, and 
long acting beta agonists provide symptomatic 
relief. Systemic steroids have been shown to be 
beneficial in some cases by possibly reducing the 
inflammatory response induced by the secretions 
of PNEC [2]. Azithromycin has also shown benefit 
in stabilizing the clinical course in some cases, 
possibly due to its immunomodulatory effects 
[10]. Therapy with somatostatin analogues (SSA) 
has been shown to improve the symptoms in some 
patients with DIPNECH, possibly by reducing 
hyperplasia and fibrosis by suppression of PNEC 
peptide production [11, 12]. 
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Alteration in activity of mammalian target 
of rapamycin (mTOR) has been found in many 
tumors, including neuroendocrine tumors [13]. 
Rossi et al. tested phosphorylated-mTOR (p-mTOR) 
and its major target, ribosomal p70S6-kinase 
(p70S6K) in four patients with DIPNECH as-
sociated with carcinoids and tumorlets [14]. 
They found a diffuse expression of p-mTOR and 
p70S6K in all neuroendocrine lesions. Sirolimus, 
an inhibitor of (mTOR) was successfully used in 
a patient with DIPNECH and carcinoid tumorlets 
recently [15]. Future studies are required to eva-
luate the role of mTOR inhibitors as a specific 
therapy for DIPNECH and associated pulmonary 
neuroendocrine tumors. 
Conclusion
Diffuse idiopathic pulmonary neuroendocri-
ne cell hyperplasia can present as a syndrome of 
obstructive and/or interstitial lung disease. DIP-
NECH should be considered as a differential for 
subacute/chronic pulmonary disease in nonsmo-
ker middle-aged females presenting with progres-
sive dyspnea, wheezing and evidence of mosaic 
attenuation, pulmonary nodules, or interstitial 
changes on CT. It is also commonly associated 
with tumorlets or carcinoid tumors. Corticoste-
roids, azithromycin, and somatostatin analogues 
have been shown to be of benefit in reported cases 
of DIPNECH. Once the diagnosis is confirmed by 
biopsy, Octreotide scan can be a valuable tool for 
guidance of therapy and evaluating response.
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